細胞・遺伝子治療市場：製品、送達方法、用途、エンドユーザー別-2025-2030年の世界予測

細胞・遺伝子治療市場は、2023年に277億米ドルと評価され、2024年には346億3,000万米ドルに達すると予想され、CAGR 25.39％で成長し、2030年には1,350億4,000万米ドルに達すると予測されています。

細胞・遺伝子治療（CGT）には、病気の治療や予防のために患者の細胞に遺伝物質を導入する生物学的治療の利用が含まれます。この発展途上の分野は、特に希少遺伝性疾患、がん、特定の慢性疾患など、アンメット・メディカル・ニーズへの対応に不可欠です。ゲノム研究、先進的臨床試験への投資の増加、FDAの再生医療先進治療指定のような迅速な規制経路による促進が、成長の触媒となっています。CAR-Tのような治療法が顕著な寛解率を示している腫瘍学から、神経疾患や心血管疾患を治療する再生医療まで、その応用範囲は多岐にわたる。最終用途の可能性は、病院、がん治療センター、専門クリニックにまで広がっています。市場は、CRISPR技術の進歩、個別化医療アプローチ、慢性疾患の有病率の増加によって大きな成長を遂げています。CGTがカバーする適応症の拡大、強固な製造能力の確立、治療の特異性と送達メカニズムを強化するためのバイオ製薬企業との提携にチャンスがあります。しかし、高い開発・治療コスト、複雑な製造工程、厳しい規制要件などの課題も残されています。さらに、遺伝子組み換えに対する倫理的な懸念や長期的な影響の可能性がハードルとなっています。イノベーションを促進するためには、既製の同種療法、効率的な遺伝子デリバリーのためのベクター設計の強化、標的療法のためのAI主導型創薬などの研究が大きな進歩をもたらす可能性があります。さらに、戦略的な価格設定モデルや綿密な官民連携を通じて患者アクセスを強化すれば、市場の障壁に対処できます。市場の成長は現在ダイナミックであり、急速な技術進歩や承認率の上昇に拍車がかかっているが、生産スケーラビリティの問題や償還状況の変動によって抑制されています。今後、細胞・遺伝子治療分野の急成長するビジネスチャンスを活かすためには、デリバリーの課題を克服し、製造プロセスを最適化し、患者中心のモデルを優先させることが極めて重要です。

市場力学：急速に進化する細胞・遺伝子治療市場の主要市場インサイトを公開

細胞・遺伝子治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の有病率の上昇と遺伝子治療の重要性
  • ヘルスケア支出の増加と相まって高まる遺伝子・細胞治療への認識
  • 臨床試験数の大幅な増加と政府認可の増加
• 市場抑制要因
  • 遺伝子・細胞治療に伴う高コスト
• 市場機会
  • 細胞・遺伝子開発における高度な分析技術の出現
  • 製薬・バイオ医薬品研究への投資の増加
• 市場の課題
  • 細胞・遺伝子治療に対する償還政策の未整備

ポーターの5つの力：細胞・遺伝子治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：細胞・遺伝子治療市場における外部からの影響の把握

外部マクロ環境要因は、細胞・遺伝子治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析細胞・遺伝子治療市場における競合情勢の把握

細胞・遺伝子治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス細胞・遺伝子治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、細胞・遺伝子治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨細胞・遺伝子治療市場における成功への道筋を描く

細胞・遺伝子治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加と遺伝子治療の重要性
    • 遺伝子・細胞治療に対する意識の高まりとヘルスケア費の増加
    • 臨床試験数の大幅な増加と政府承認の増加
  • 抑制要因
    • 遺伝子・細胞治療に伴う高額な費用
  • 機会
    • 細胞・遺伝子開発における先進分析技術の出現
    • 医薬品およびバイオ医薬品調査への投資増加
  • 課題
    • 細胞・遺伝子治療に対する償還ポリシーが利用できない
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 細胞・遺伝子治療市場：製品別

• 細胞療法
• 遺伝子治療

第7章 細胞・遺伝子治療市場配送方法別

• 生体外
• In vivo

第8章 細胞・遺伝子治療市場：用途別

• 皮膚科
• 筋骨格
• 腫瘍学

第9章 細胞・遺伝子治療市場：エンドユーザー別

• 外来手術センター
• がんケアセンター
• 病院
• 創傷ケアセンター

第10章 南北アメリカの細胞・遺伝子治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の細胞・遺伝子治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの細胞・遺伝子治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abeona Therapeutics Inc.
• Adaptimmune Limited
• AGC Biologics
• Alnylam Pharmaceuticals, Inc.
• American Gene Technologies Inc.
• Amgen Inc.
• AnGes, Inc.
• Astellas Gene Therapies
• Beacon Therapeutics Limited
• Biogen Inc.
• bluebird bio, Inc.
• Cellectis SA
• Editas Medicine, Inc.
• F. Hoffmann-La Roche Ltd
• Immuneel Therapeutics Private Limited
• Ionis Pharmaceuticals, Inc.
• Merck KGaA
• Mustang Bio, Inc.
• Novartis AG
• Orchard Therapeutics PLC
• Poseida Therapeutics, Inc.
• Sangamo Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Sibiono GeneTech Co. Ltd.
• Uniqure N.V.

LIST OF FIGURES

• FIGURE 1. CELL & GENE THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. CELL & GENE THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELL & GENE THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL & GENE THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. CANADA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 37. CANADA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. CHINA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 59. CHINA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. INDIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 63. INDIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. ITALY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 132. ITALY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. POLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 148. POLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. QATAR CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 152. QATAR CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Cell & Gene Therapy Market was valued at USD 27.70 billion in 2023, expected to reach USD 34.63 billion in 2024, and is projected to grow at a CAGR of 25.39%, to USD 135.04 billion by 2030.

Cell and gene therapy (CGT) encompasses the use of biological treatments that modify or introduce genetic material into a patient's cells to treat or prevent disease. This evolving sector is notably vital for addressing unmet medical needs, especially for rare genetic disorders, cancers, and certain chronic conditions. Increasing investments in genomic research, advanced clinical trials, and the acceleration through expedited regulatory pathways like the FDA's regenerative medicine advanced therapy designation have catalyzed growth. Applications span from oncology, where therapies like CAR-T have shown remarkable remission rates, to regenerative medicine treating neurological disorders and cardiovascular diseases. The end-use potential extends to hospitals, cancer treatment centers, and specialized clinics. The market is experiencing significant growth driven by advances in CRISPR technology, personalized medicine approaches, and an increasing prevalence of chronic diseases. Opportunities lie in expanding the indications covered by CGT, establishing robust manufacturing capabilities, and biopharma collaborations to enhance therapy specificity and delivery mechanisms. However, challenges remain, including high development and therapy costs, complex manufacturing processes, and strict regulatory requirements. Additionally, ethical concerns over genetic modifications and potential long-term impacts pose hurdles. To foster innovation, research into off-the-shelf allogeneic therapies, enhanced vector designs for efficient gene delivery, and AI-driven drug discovery for targeted therapies can provide significant advancements. Furthermore, enhancing patient access through strategic pricing models and in-depth public-private partnerships can address market barriers. Market growth is currently dynamic, spurred by rapid technological advancements and growing approval rates, yet tempered by production scalability issues and variable reimbursement landscapes. Moving forward, a focus on overcoming delivery challenges, optimizing manufacturing processes, and prioritizing patient-centric models will be pivotal in capitalizing on the burgeoning opportunities of the cell and gene therapy sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Market

The Cell & Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of chronic diseases and significance for gene therapy treatment
  • Growing awareness of gene & cell therapies coupled with increase in healthcare expenditure
  • Significant growth in numbers of clinical trials and increasing governmental approvals
• Market Restraints
  • High costs asscoiated with the gene and cell therapy treatment
• Market Opportunities
  • Emergence of advanced analytical technologies in development of cell & gene
  • Rising investments in pharmaceutical and biopharmaceutical research
• Market Challenges
  • Unavailability of reimbursement policies for cell & gene therapies

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Market

A detailed market share analysis in the Cell & Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Market

A strategic analysis of the Cell & Gene Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Limited, AGC Biologics, Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Astellas Gene Therapies, Beacon Therapeutics Limited, Biogen Inc., bluebird bio, Inc., Cellectis SA, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd, Immuneel Therapeutics Private Limited, Ionis Pharmaceuticals, Inc., Merck KGaA, Mustang Bio, Inc., Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Sibiono GeneTech Co. Ltd., and Uniqure N.V..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Cell Therapy and Gene Therapy.
• Based on Delivery Method, market is studied across Ex Vivo and In Vivo.
• Based on Application, market is studied across Dermatology, Musculoskeletal, and Oncology.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Care Centers, Hospitals, and Wound Care Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases and significance for gene therapy treatment
    • 5.1.1.2. Growing awareness of gene & cell therapies coupled with increase in healthcare expenditure
    • 5.1.1.3. Significant growth in numbers of clinical trials and increasing governmental approvals
  • 5.1.2. Restraints
    • 5.1.2.1. High costs asscoiated with the gene and cell therapy treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of advanced analytical technologies in development of cell & gene
    • 5.1.3.2. Rising investments in pharmaceutical and biopharmaceutical research
  • 5.1.4. Challenges
    • 5.1.4.1. Unavailability of reimbursement policies for cell & gene therapies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell & Gene Therapy Market, by Product

• 6.1. Introduction
• 6.2. Cell Therapy
• 6.3. Gene Therapy

7. Cell & Gene Therapy Market, by Delivery Method

• 7.1. Introduction
• 7.2. Ex Vivo
• 7.3. In Vivo

8. Cell & Gene Therapy Market, by Application

• 8.1. Introduction
• 8.2. Dermatology
• 8.3. Musculoskeletal
• 8.4. Oncology

9. Cell & Gene Therapy Market, by End-User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Cancer Care Centers
• 9.4. Hospitals
• 9.5. Wound Care Centers

10. Americas Cell & Gene Therapy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cell & Gene Therapy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abeona Therapeutics Inc.
• 2. Adaptimmune Limited
• 3. AGC Biologics
• 4. Alnylam Pharmaceuticals, Inc.
• 5. American Gene Technologies Inc.
• 6. Amgen Inc.
• 7. AnGes, Inc.
• 8. Astellas Gene Therapies
• 9. Beacon Therapeutics Limited
• 10. Biogen Inc.
• 11. bluebird bio, Inc.
• 12. Cellectis SA
• 13. Editas Medicine, Inc.
• 14. F. Hoffmann-La Roche Ltd
• 15. Immuneel Therapeutics Private Limited
• 16. Ionis Pharmaceuticals, Inc.
• 17. Merck KGaA
• 18. Mustang Bio, Inc.
• 19. Novartis AG
• 20. Orchard Therapeutics PLC
• 21. Poseida Therapeutics, Inc.
• 22. Sangamo Therapeutics, Inc.
• 23. Sarepta Therapeutics, Inc.
• 24. Sibiono GeneTech Co. Ltd.
• 25. Uniqure N.V.